摘要
目的:为我国基本药物遴选方法的完善提供参考。方法:阐述我国基本药物目录遴选原则和世界卫生组织遴选方法的沿革,并分析我国基本药物遴选目前存在的问题,提出解决现存问题的方法。结果与结论:我国基本药物目录遴选方法不尽合理,部分入选药物在安全性和临床需要方面循证证据不足,难以满足临床需求和保证药品安全。应尽快建立科学、合理、客观的遴选标准,在遴选中引入循证医学证据和药物经济学方法,以完善我国基本药物目录。
OBJECTIVE： To provide reference for the adjustment of selection methods for essential drugs in China. METHODS： The selection principle of essential drugs list and selection method of WHO were analyzed, and the problems of essential drugs selection were analyzed and some method to resolving exsiting problems were put forward. RESULTS ＆ CONCLUSION： The selection method of essential drugs list is not reasonable, and the safety of drug selection and clinical demand lack of evidence. It is difficult to meet clinical demand and ensure drug safety. Scientific, rational and objective selection criteria should be established as soon as possible, to avoid excessive subjective opinions of experts and introduce evidence-based medicine and pharmacoeconomic methods to improve essential drugs list in China.
出处
《中国药房》
CAS
CSCD
2013年第12期1057-1059,共3页
China Pharmacy
